Avita Corporation AI Stock Analysis
Avita Corporation (4735) AI Stock Analysis
Avita Corporation
(TPEx:4735)
Avita scores in the upper-middle range, driven by a near debt-free balance sheet and a sharp valuation discount — a P/E under 6 and a double-digit dividend yield. Offsetting this are two meaningful risks: stagnant revenue that remains far below prior peaks, and a swing to deeply negative free cash flow as capital spending ramps while operating cash conversion weakens. Technically, the stock holds above its 100- and 200-day averages but has lost short-term momentum, with price below the 20- and 50-day averages and a negative MACD. The investment case hinges on whether the current capex cycle restores revenue growth and cash generation; until then, the low leverage and cheap valuation provide downside support rather than a catalyst.
Avita Corporation (4735) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.39B
- Dividend Yield
- 10.29%
- Average Volume (3M)
- 69.65K
- Price to Earnings (P/E)
- 6.0
- Beta (1Y)
- 0.32
- Revenue Growth
- 4.61%
- EPS Growth
- 207.89%
- Country
- TW
- Employees
- 84
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Avita Corporation Business Overview & Revenue Model
Company Description
AViTA Corporation, established in 1996, is headquartered in New Taipei City, Taiwan. The company focuses on the creation and distribution of consumer medical devices for in-home use. Its extensive portfolio encompasses various personal healthcare gad...
Avita Corporation Financial Statement Overview
Summary
A very strong balance sheet (score 83) anchors the profile: debt-to-equity of just 0.03, equity funding ~74% of assets, and 19% equity growth give Avita substantial financial flexibility. The income statement (score 60) shows a solid margin-led recovery — gross margin up to 31.6%, operating margin to 10.1% and net income +61% to NT$93.2M — but revenue was flat at NT$936.4M and remains ~64% below the 2020 peak, so earnings growth depends on cost and mix rather than volume. Cash flow is the clear weak spot (score 40): operating cash flow fell 67% to NT$64.5M, covering only ~69% of net income, and heavy capex pushed free cash flow to -NT$197.7M versus +NT$108.7M a year earlier. The debt-free structure makes this investment cycle sustainable near term, but cash conversion must recover for the earnings rebound to be convincing.
Income Statement
60NeutralBalance Sheet
83Very PositiveCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 972.61M | 936.39M | 927.30M | 879.08M | 1.20B | 2.33B |
| Gross Profit | 306.90M | 295.73M | 254.59M | 264.79M | 356.81M | 674.50M |
| EBITDA | 160.85M | 154.52M | 125.63M | 105.32M | 206.71M | 468.49M |
| Net Income | 231.50M | 93.19M | 57.88M | 42.72M | 101.13M | 315.47M |
Balance Sheet | ||||||
| Total Assets | 1.80B | 1.35B | 1.19B | 1.24B | 1.34B | 1.69B |
| Cash, Cash Equivalents and Short-Term Investments | 686.71M | 432.71M | 526.15M | 540.24M | 453.36M | 365.43M |
| Total Debt | 262.79M | 31.89M | 28.94M | 46.16M | 77.34M | 299.55M |
| Total Liabilities | 673.53M | 358.63M | 352.93M | 350.80M | 426.61M | 742.75M |
| Stockholders Equity | 1.13B | 996.01M | 838.11M | 888.28M | 911.18M | 952.03M |
Cash Flow | ||||||
| Free Cash Flow | -150.37M | -197.70M | 108.73M | 180.74M | 425.19M | 165.08M |
| Operating Cash Flow | 69.42M | 64.46M | 192.52M | 212.02M | 490.50M | 237.01M |
| Investing Cash Flow | -444.24M | -326.91M | -42.96M | -90.59M | -75.08M | -53.48M |
| Financing Cash Flow | 133.31M | 75.61M | -154.83M | -93.77M | -318.95M | -416.47M |
Avita Corporation Peers Comparison
Overall Rating
- TW:473567Neutral
TW:664964Neutral
TW:663762Neutral
TW:416161Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4735 | 67Neutral | TWD 1.40B | 6.03 | ― | 10.29% | 4.61% | 207.89% |
| TW:6649 | 64Neutral | TWD 1.51B | 45.55 | ― | 2.81% | -24.55% | -85.90% |
| TW:6637 | 62Neutral | TWD 1.46B | 10.00 | ― | 8.24% | -13.07% | -26.73% |
| TW:4161 | 61Neutral | TWD 1.22B | 11.45 | ― | 3.32% | 7.54% | 35.87% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4735 | Avita Corporation | 35.95 | 6.30 | 21.26% | |
| TW:4161 | Bioptik Technology, Inc. | 21.10 | -4.55 | -17.73% | |
| TW:6637 | Medical Imaging Corp. | 54.60 | -22.26 | -28.96% | |
| TW:6649 | Taiwan Biomaterial Co., Ltd. | 35.65 | -13.98 | -28.16% | |
| TW:6847 | PuriBlood Medical Co.,Ltd. | 70.40 | -2.46 | -3.38% | |
| TW:6857 | Acer Medical Inc. | 89.90 | -28.60 | -24.14% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026